Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
4.230
+0.150 (3.68%)
At close: Dec 20, 2024, 4:00 PM
4.220
-0.010 (-0.24%)
After-hours: Dec 20, 2024, 7:59 PM EST

Company Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.

Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.

The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.
Biomea Fusion logo
Country United States
Founded 2017
IPO Date Apr 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 103
CEO Thomas Butler

Contact Details

Address:
900 Middlefield Road, 4th Floor
Redwood City, California 94063
United States
Phone 650 980 9099
Website biomeafusion.com

Stock Details

Ticker Symbol BMEA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001840439
CUSIP Number 09077A106
ISIN Number US09077A1060
SIC Code 2834

Key Executives

Name Position
Thomas Andrew Butler Co-Founder, Chairman and Chief Executive Officer
Ramses M. Erdtmann Co-Founder, President, Chief Operating Officer and Director
Franco Valle CPA Chief Financial Officer and Principal Accounting Officer
Dr. Juan Pablo Frias M.D. Chief Medical Officer
Heow Tan Chief Technology and Quality Officer
Naomi Cretcher Chief People Officer
Dr. Thorsten Kirschberg Ph.D. Executive Vice President of Chemistry
Dr. Stephan Morris M.D. Chief Development Officer
Ravi Upasani Executive Vice President of Intellectual Property
Caroline Perez- Dupont Senior Vice President of Contracts

Latest SEC Filings

Date Type Title
Dec 20, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024 8-K Current Report
Oct 29, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Sep 27, 2024 8-K Current Report
Jul 31, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jul 18, 2024 UPLOAD Filing
Jul 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals